Manhattan Pharmaceuticals received Swiss regulatory approval to begin its Phase IIa study with oral Oleoyl-estrone (OE), the company’s drug candidate for the treatment of obesity. The single center, Phase IIa study is a randomized, double-blind, placebo-controlled, parallel group study designed to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day dosing cycles in obese adult subjects. Subjects will be randomly enrolled in one of four treatment groups. Dose level...